1[1]Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Science,1996,274(5286):373- 376.
2[2]Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer[J]. J Clin Oncol, 2001,19(2):289- 298.
3[3]Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med,2000,6(8):879- 885.
4[4]Ganly I, Eckhardt SG, Rodriguez GI, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer[J]. Clin Cancer Res,2000,6(3):798- 806.
5[5]Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors[J]. Hum Gene Ther,2001,12(3): 219- 226.
6[6]Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial[J]. Gene Ther, 2001, 8(4): 308- 315.
7[7]Heise C,Wukkuans AM,Xue S, et al. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy[J]. Cancer Res, 1999, 59: 2623- 2628.
8[8]Heise C,Ganly I,Kim YT,et al.Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status[J]. Gene Ther, 2000,7:1925- 1929.
9[9]Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents[J]. Nat Med,1997,3(6):639- 645.
10[10]Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy[J]. Cancer Res, 2000,60(5):1193- 1196.
